title: Phase II cancer prevention clinical trials.
abstract: The development of agents to prevent cancer requires an iterative process of target identification, preclinical testing, and early and late phase clinical trials to establish efficacy and safety. Since phase III definitive efficacy trials with cancer endpoints require a lengthy timeframe and considerable resources for completion, it is critical to first optimize agent delivery and trial design and to determine preliminary efficacy via the conduct of phase II trials. Phase II trials vary considerably in their endpoints, cohorts, and designs due to differences in the process of carcinogenesis and ability to sample tissues across different target organs. However, the goal of all such trials is to provide evidence of interference with the development of cancer and to identify safety signals that would limit the benefit from interventions.
authors.affiliation: Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. szaboe@mail.nih.gov
authors.forename: Eva
authors.initials: E
authors.lastname: Szabo
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000517:prevention & control*
references.citation: Mol Cancer Ther. 2008 Apr;7(4):972-9
references.pmid: 18375820
references.citation: J Natl Cancer Inst. 2003 Mar 19;95(6):470-8
references.pmid: 12644540
references.citation: Nat Rev Cancer. 2002 Jan;2(1):19-27
references.pmid: 11902582
references.citation: Clin Cancer Res. 2003 Jan;9(1 Pt 2):502S-10S
references.pmid: 12538507
references.citation: Chest. 2000 Jun;117(6):1572-6
references.pmid: 10858385
references.citation: J Natl Cancer Inst. 1990 Apr 4;82(7):555-60
references.pmid: 2179569
references.citation: Sci Transl Med. 2010 Apr 7;2(26):26ra25
references.pmid: 20375364
references.citation: Cancer Invest. 2008 Feb;26(1):1-10
references.pmid: 18181038
references.citation: JAMA. 2006 Jun 21;295(23):2727-41
references.pmid: 16754727
references.citation: Lancet. 2009 Jul 25;374(9686):301-14
references.pmid: 19586656
references.citation: Eur J Cancer. 2003 Apr;39(6):793-9
references.pmid: 12651205
references.citation: Clin Cancer Res. 2002 Feb;8(2):314-46
references.pmid: 11839647
references.citation: N Engl J Med. 2007 May 10;356(19):1928-43
references.pmid: 17494926
references.citation: J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
references.pmid: 2593165
references.citation: Cancer Prev Res (Phila). 2010 Feb;3(2):128-31
references.pmid: 20103726
references.citation: Clin Cancer Res. 2002 Oct;8(10):3105-17
references.pmid: 12374678
references.citation: J Natl Cancer Inst. 2002 Jul 3;94(13):1001-9
references.pmid: 12096085
references.citation: N Engl J Med. 2010 Mar 18;362(11):986-93
references.pmid: 20237344
references.citation: J Natl Cancer Inst. 2007 May 2;99(9):715-26
references.pmid: 17470739
references.citation: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references.pmid: 9747868
references.citation: Nat Rev Cancer. 2006 Nov;6(11):867-74
references.pmid: 17036038
references.citation: Clin Cancer Res. 2006 Jun 15;12(12):3661-97
references.pmid: 16778094
references.citation: Breast Cancer Res Treat. 2007 Nov;106(1):75-84
references.pmid: 17221152
references.citation: Clin Cancer Res. 2005 Jan 1;11(1):12-9
references.pmid: 15671523
references.citation: Cancer Prev Res (Phila). 2008 Jun;1(1):32-8
references.pmid: 18841250
references.citation: Am J Respir Crit Care Med. 2001 Nov 1;164(9):1688-93
references.pmid: 11719311
references.citation: Nature. 2008 Oct 23;455(7216):1069-75
references.pmid: 18948947
references.citation: Cancer Prev Res (Phila). 2010 Feb;3(2):148-59
references.pmid: 20103722
references.citation: Gastroenterology. 2006 Dec;131(6):1674-82
references.pmid: 17087947
references.citation: Cancer. 1984 Feb 1;53(3):563-8
references.pmid: 6537892
references.citation: BMJ. 2000 Aug 5;321(7257):323-9
references.pmid: 10926586
references.citation: N Engl J Med. 1996 May 2;334(18):1150-5
references.pmid: 8602180
references.citation: Ann Oncol. 2005 Nov;16(11):1811-6
references.pmid: 16087693
references.citation: Clin Cancer Res. 2004 Oct 1;10(19):6502-11
references.pmid: 15475437
references.citation: N Engl J Med. 1994 Apr 14;330(15):1029-35
references.pmid: 8127329
references.citation: Nat Rev Drug Discov. 2009 Mar;8(3):213-25
references.pmid: 19247304
references.citation: J Natl Cancer Inst. 2007 Apr 4;99(7):545-57
references.pmid: 17405999
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1382-91
references.pmid: 16835340
references.citation: Cancer Invest. 2005;23(3):274-80
references.pmid: 15945512
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: N Engl J Med. 2000 Jun 29;342(26):1946-52
references.pmid: 10874062
references.citation: Clin Cancer Res. 2000 Feb;6(2):357-62
references.pmid: 10690511
references.citation: N Engl J Med. 2005 Mar 17;352(11):1092-102
references.pmid: 15713943